Abstract
Objective To investigate clinical efficacy of adefovir dipivoxil (ADV) combined with interferon α-2b in treatment of chronic hepatitis B. Methods During Jan 2008 to Dec 2014, ninety patients with chronic hepatitis B were divided into adefovir dipivoxil group (33 cases), interferon group (28 cases), and adefovir dipivoxil combined with interferon α-2b group (29 cases). Alanine aminotransferase (ALT) normalization rate, negative rate of HBV-DNA, and HBeAg/anti-HBe seroconversion rates were evaluated among three groups. Results After 48 weeks of treatment, HBeAg negative rate, HBV-DNA negative rate, and ALT normalization rate of combination group were significantly higher than that of interferons α-2b group and adefovir dipivoxil group (P<0.05). Conclusions Adefovir dipivoxil combined with interferon α-2b treatment can inhibit the hepatitis B virus, increase the negative rate of HBV-DNA and HBeAg, and reduce liver cell damage. Key words: Phosphonic acids/AD; Adenine/AA/AD; Interferon alfa-2b/AA/AD; Hepatitis B, chronic/DT
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
